Navigation Links
New Evidence Supports HPV Vaccine
Date:7/6/2009

Industry-funded study showed high levels of protection against human papillomavirus

MONDAY, July 6 (HealthDay News) -- The human papillomavirus (HPV) vaccine is highly effective at preventing precancerous cervical lesions that can lead to cervical cancer, a new study shows.

The researchers also found that the HPV-16/18 AS04-adjuvanted vaccine also appears to protect against other cancer-causing HPV types closely related to HPV-16/18, most notably HPV-31 and HPV-45.

The study of women aged 15 to 25, who received three vaccine doses over six months, found that it was as much as 98 percent effective against HPV-16/18, and between 37 percent and 54 percent effective against 12 other cancer-causing HPV types.

HPV-16/18 causes about 70 percent of cervical cancer cases, while the remaining 30 percent of cases are caused by other cancer-causing HPV types. The cross-protective effect of the HPV-16/18 vaccine could provide an additional 11 percent to 16 percent protection against cervical cancer.

"Although the importance of continued tests for Pap or HPV in vaccinated and unvaccinated women must be emphasized, HPV vaccination has the potential to substantially reduce the incidence of cervical cancer and precancer, and the numbers of colposcopy referrals and cervical excision procedures," concluded Dr. Jorma Paavonen, of the University of Helsinki in Finland, and colleagues.

The study, which was funded by GlaxoSmithKline Biologicals, maker of the HPV-16/18 AS04-adjuvanted vaccine Cervarix, appears online July 7 and in an upcoming print issue of The Lancet.

In an accompanying editorial, two experts wrote that men must also be included in efforts to halt the spread of HPV.

"Currently, the targets for HPV vaccination are girls and young women aged 11 to 26 years prior to sexual debut," noted Karin B. Michels, of Harvard Medical School in Boston, and Dr. Harald zur Hausen, of the Ger
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
2. No strong evidence linking amateur boxing with long-term brain injury
3. AHRQ Announces Next Phase of Its Evidence-Based Practice Center Program
4. Vanderbilt Medical Center chosen as Evidence-based Practice Center
5. Little Evidence Silicone Breast Implants Harm Health
6. Consumers Should Demand Evidence, Not Guesswork, On Meat-Cancer Links
7. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
8. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
9. Scientific evidence of the significant anti-cancer effect of milk thistle
10. Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
11. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Evidence Supports HPV Vaccine
New Evidence Supports HPV Vaccine
Breaking Medicine Technology:Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Vivakor Announces New Acquisition Strategy 2Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 1YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 3YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 5YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 6U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 1U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 3New Hampshire Rx Card Launching Statewide 5239 1New Hampshire Rx Card Launching Statewide 5239 2